Arteriovenous Malformation: Types, Tests And Care

Sources checked on 9 October 2026. This guide covers AVM terminology, symptoms, tests, care options, research, and practical questions for specialist appointments.

What Is an Arteriovenous Malformation?

An arteriovenous malformation, or AVM, is an abnormal network connecting arteries and veins without the usual intervening capillaries. Blood can pass rapidly through this network, changing circulation in nearby tissue. AVMs can occur in the brain, spinal cord, or other parts of the body. Some remain unnoticed until imaging finds them; others cause symptoms or bleeding. Brain symptoms can include seizures, headaches, weakness, altered sensation, or difficulties with vision, speech, and coordination. Those symptoms are not specific enough to diagnose an AVM. Its location and effects must be established before treatment choices make sense. [3]

Recognize a Stroke Emergency

Sudden facial drooping, weakness or numbness on one side, difficulty speaking, loss of vision, or severe new imbalance requires emergency medical assessment. A sudden severe headache can also accompany a stroke. Call the local emergency number immediately, such as 999 in the United Kingdom or 911 in the United States. Symptoms that disappear still need urgent assessment; improvement does not make the episode safe to ignore. Do not drive yourself to hospital. These warning signs matter whether an AVM is already known or has never been diagnosed, because stroke can happen at any age. [1]

Seizures Can Also Need Emergency Help

A first seizure needs emergency assessment. Call an ambulance when a seizure lasts longer than the person’s usual pattern, continues beyond five minutes when their usual duration is unknown, or repeats without recovery of consciousness. Breathing difficulty, serious injury, or failure to regain consciousness also warrants emergency help. For someone with established epilepsy, an agreed clinical emergency plan can specify the response to their usual seizures. An AVM article cannot replace that plan. The important distinction is between a familiar event with a documented response and a new, prolonged, or complicated episode requiring urgent care. [2]

Why the Exact Name Matters

The 2025 ISSVA classification separates vascular malformations principally by their blood-flow characteristics and associated features. AVMs belong among fast-flow abnormalities; venous and many other vascular malformations have different flow patterns. A vascular malformation is also different from a vascular tumor. The name therefore conveys clinically useful information rather than simply describing a visible lump or birthmark. Before applying information found online, check the actual diagnosis in the clinical report. Evidence about a brain AVM should not automatically be applied to a slow-flow venous lesion, an arteriovenous fistula, or a malformation in another organ. [4]

Spinal AVMs Have Different Effects

A spinal AVM involves vessels associated with the spinal cord. Changes in circulation, pressure on the cord, or hemorrhage can produce leg pain, weakness, numbness, difficulty walking, and bladder or bowel disturbance. Symptoms may evolve gradually or begin abruptly. The presentation can resemble several other spinal conditions, including a dural fistula, so symptoms alone cannot identify the lesion. MRI helps examine the cord, while angiography may be needed to define the abnormal vessels. Management depends on this anatomy and the neurological changes. Brain-AVM trial results do not establish the best treatment for spinal AVMs. [5]

Peripheral AVMs Affect Local Tissue

Peripheral AVMs occur outside the central nervous system and can affect skin, muscle, or other soft tissues. Pain, swelling, discoloration, bleeding, and occasionally ulceration can interfere with daily function. Being noncancerous does not mean a malformation is harmless. Assessment considers symptoms, the extent of the lesion, and how treatment could affect surrounding structures. Some people are observed, while others receive procedures intended to control troublesome symptoms. Treatment can involve several sessions, and persistent or recurring problems may need reassessment. Expectations should address pain and function as well as the appearance or size of the malformation. [6]

Lung AVMs Create a Different Risk

Pulmonary AVMs connect blood vessels within the lungs, allowing some blood to bypass normal filtering and oxygen exchange. Their complications can include low oxygen levels, stroke caused by material crossing into the arterial circulation, and brain abscess. This is different from a brain AVM bleeding directly into brain tissue. The British Thoracic Society recommends specialist assessment of radiologically visible pulmonary AVMs, including consideration of embolization. Investigation also considers an association with hereditary hemorrhagic telangiectasia. The absence of striking breathing symptoms does not reliably exclude a clinically important pulmonary lesion or remove the need for appropriate specialist advice. [7]

An AV Fistula Is Not the Same Lesion

An arteriovenous fistula is an abnormal direct connection between an artery and a vein rather than the intervening vessel network typical of an AVM. Dural fistulas arise in the covering around the brain or spinal cord. Depending on their drainage, they can cause a pulse-synchronous whooshing sound, eye symptoms, neurological problems, or hemorrhage. Their risk assessment and treatment planning follow the fistula’s particular anatomy. A report using the word fistula therefore deserves its own explanation. Similar symptoms and overlapping procedures do not make fistulas interchangeable with the brain AVMs studied in ARUBA. [8]

Cavernous Malformations Need Separate Guidance

A cavernous malformation is another vascular condition that can occur in the brain or spinal cord. It is not the same as a fast-flow AVM, even though both can cause seizures or bleeding. MRI, including sequences sensitive to blood products, plays a central role in cavernous-malformation assessment. The updated 2025 clinical consensus guidance addresses this condition separately, with decisions influenced by symptoms, lesion location, previous hemorrhage, and familial features. An AVM’s angiographic grading system or treatment evidence should not be substituted for this guidance. Clarifying the diagnosis prevents an inappropriate comparison between two different disorders. [9]

Venous Malformations Are Usually Slow Flow

Venous malformations consist of abnormally formed veins and often have slow blood flow. Some appear as bluish swellings; others are deep in tissue and less visible. Pooling of blood and small clots within the lesion can cause discomfort, while extensive lesions may affect clotting more broadly. They differ from an AVM’s fast arterial-to-venous shunt. Imaging can help establish the diagnosis and extent. Treatment decisions may involve observation, specialist compression advice, sclerotherapy, or selected surgery. Those options belong to venous-malformation care and should not be assumed suitable for an AVM simply because both involve abnormal vessels. [10]

How Imaging Clarifies the Diagnosis

Brain imaging answers different questions at different stages. CT can show bleeding and other structural changes, while CT angiography adds information about vessels. MRI provides detailed views of brain tissue and the lesion’s relationship to nearby structures; magnetic resonance angiography examines circulation. Catheter angiography offers detailed mapping of feeding arteries and draining veins for treatment planning. Clinicians combine these findings with the history and neurological examination. A scan can also discover an AVM incidentally during an unrelated investigation. Finding a lesion establishes a need for assessment, but does not by itself determine whether an intervention is worthwhile. [11]

Catheter Angiography Has Benefits and Risks

Diagnostic cerebral angiography uses a catheter, contrast material, and X-rays to examine blood flow with high spatial and time resolution. The 2026 SNIS guidance supports its role when noninvasive findings remain uncertain and when detailed vascular information is needed for an intervention. It is an invasive investigation, so consent should address the reason for testing, alternatives, and relevant complications. These include neurological injury, injury to blood vessels, access-site bleeding, and contrast-related problems. The team should explain its own complication rates and discuss the findings afterward. A detailed test is valuable when its information can meaningfully guide care. [12]

Bleeding Estimates Need Clinical Context

The AHA/ASA statement cites pooled untreated brain-AVM data with annual hemorrhage estimates of approximately 1.3% for previously unruptured lesions and 4.8% for previously ruptured lesions. These are group averages during observed follow-up, not lifetime probabilities or predictions for one person. Prior bleeding, time since hemorrhage, and vascular anatomy can change the assessment. The figures do not describe peripheral or spinal AVMs. After a brain hemorrhage, immediate care addresses the bleed and its consequences; decisions about treating the underlying AVM then depend on clinical stability and anatomy. Emergency management of the hemorrhage and treatment of the underlying AVM are related but distinct decisions. [13]

What ARUBA Actually Found

ARUBA randomized adults with untreated, unruptured brain AVMs considered suitable for intervention. Its final follow-up, published in 2020, reported death or symptomatic stroke in 15 of 110 participants assigned medical management alone and 41 of 116 assigned medical management plus intervention, over a mean 50.4 months. This important randomized evidence favored medical management during that period. It does not address ruptured AVMs, children, or lesions elsewhere in the body. Intervention combined several approaches, and the study cannot settle every technique or anatomical subgroup. The follow-up also cannot establish outcomes across an entire remaining lifetime. [14]

Newer Observational Evidence Has Limits

A 2025 analysis of 1,770 people in China’s MATCH registry used observational data to emulate a trial. Intervention was associated with better estimated survival without AVM-related hemorrhage or death at five and ten years. However, this was not random assignment, residual confounding remained possible, and the main outcome did not capture every neurological or treatment-related harm. Results came from specialized centers, and benefits were not uniform across lesion types. Its endpoint differs from ARUBA’s symptomatic stroke-or-death endpoint. It adds evidence for individual discussion; it does not overturn the randomized trial or prove that every unruptured AVM should undergo surgery. [15]

A Surgical Grade Is Not a Rupture Forecast

The Spetzler-Martin grading system was developed to estimate the risks of operating on a brain AVM. It considers lesion size, the importance of nearby brain functions, and whether venous drainage is deep. A lesion near language, movement, or visual pathways may create different operative concerns from one elsewhere. The grade helps organize discussion and compare clinical series. It does not function as a standalone calculation of spontaneous bleeding risk. A low grade is not an instruction to operate, and a higher grade is not a complete treatment plan. Additional clinical features and the proposed technique remain relevant. [16]

Microsurgery Offers Immediate Removal

Microsurgery aims to remove a brain AVM while preserving the surrounding brain and its normal circulation. Complete removal can offer immediate elimination of the abnormal connection, whereas some other treatments act gradually. That potential benefit must be weighed against operative complications, including neurological injury, hemorrhage, disability, or death. Suitability depends heavily on anatomy and the functions at risk. Some lesions are approached with combined treatments, and some are monitored. The meaningful discussion concerns the expected result for the particular lesion, the center’s experience, and how procedural risk compares with the consequences of leaving the AVM untreated. [17]

Radiosurgery Works Over Time

Stereotactic radiosurgery directs focused radiation at a brain AVM to produce gradual vessel closure. It may be considered for selected lesions whose location makes open surgery less attractive. Closure develops over several years, may remain incomplete, and does not provide immediate protection from hemorrhage. Bleeding risk persists during the latency period, and imaging is needed to establish the response. Radiation-related swelling or injury can cause delayed neurological symptoms. ISRS guidance for lower-grade AVMs acknowledges that much of the supporting literature is observational. A treatment without an open incision still requires careful comparison of benefits, complications, and follow-up burden. [18]

Embolization Has Several Possible Roles

Endovascular embolization delivers material through a catheter to block selected abnormal vessels. For brain AVMs, it can help prepare for surgery, target a particular high-risk feature, or form part of a combined plan. Complete treatment by embolization alone is possible in selected circumstances, but SNIS guidance describes the overall curative role as uncertain. Partial flow reduction is not equivalent to confirmed elimination of the AVM. The procedure can cause ischemic or hemorrhagic injury, and repeated stages add their own exposure to risk. Its purpose should be explicit within an overall multidisciplinary strategy, rather than judged only by an immediate angiographic change. [19]

A Specialist Team Integrates the Evidence

The 2024 ARISE consensus highlighted persistent uncertainty in brain-AVM management and the value of coordinated specialist expertise. Neurosurgery, interventional neuroradiology, radiation specialists, and neurology contribute different perspectives. Their task is to connect the lesion’s anatomy with the person’s clinical situation and the realistic outcomes of available options. Expert consensus helps frame difficult decisions, but it is not a substitute for randomized evidence. ARISE also emphasized better risk prediction, common research measures, and prospective registries. These priorities explain why a responsible consultation may include uncertainty rather than a single universally accepted answer for every unruptured brain AVM. [20]

Peripheral Management Follows Its Own Pathway

VASCERN’s February 2026 AVM pathway separates central nervous system lesions from peripheral, visceral, and intracavitary malformations. It favors assessment in a specialist multidisciplinary center. For noncentral lesions, stability without symptoms may support active surveillance; symptomatic or progressive disease may prompt consideration of treatment. Options can include embolization, surgery, or selected systemic approaches within specialist care. Puberty and pregnancy planning can change follow-up needs. This pathway is an expert opinion statement that will continue to be evaluated. It helps organize care without supplying a universal procedure, medicine, or follow-up interval for every patient. [21]

Seizure Care Is a Separate Treatment Goal

When seizures occur, assessment and treatment should address the seizure disorder as well as the vascular lesion. NICE recommends individualized decisions about antiseizure treatment, considering seizure type, recurrence risk, other medicines, personal circumstances, and treatment preferences. A structural abnormality on imaging can influence the discussion after a first unprovoked seizure. Medication selection also requires attention to reproductive safety and other adverse effects. Controlling seizures does not show that an AVM has disappeared, and treating the AVM does not remove the need to review seizure care. Starting, stopping, or changing a medicine belongs within the treating clinician’s plan. [22]

Recovery Includes More Than the Scan

After an AVM-related stroke, recovery needs may include movement, communication, swallowing, vision, memory, fatigue, and emotional adjustment. A favorable scan does not describe all of these experiences. NICE’s stroke-rehabilitation guidance supports assessment across these domains and rehabilitation linked to the person’s needs and goals. Physiotherapy, occupational therapy, speech and language therapy, and psychological support may all contribute. The plan should account for fatigue and other medical issues, with family involvement when appropriate. Progress can differ between abilities, so follow-up should examine everyday function alongside the status of the vascular lesion. [23]

When an Inherited Condition Is Suspected

Hereditary hemorrhagic telangiectasia, or HHT, can involve vascular malformations in several organs. Recurrent nosebleeds, characteristic small surface vessels, organ involvement, and family history can prompt specialist assessment. Diagnosis may use clinical criteria and genetic testing. For suspected or confirmed HHT, screening and family evaluation follow syndrome-specific guidance; discovering one apparently isolated AVM does not automatically establish HHT. Pregnancy care also requires attention to pulmonary as well as brain lesions. The international guidelines emphasize individualized neurovascular decisions and appropriate specialist coordination. Genetic counseling can explain what a result means for relatives and which investigations are justified. [24]

Other Genetic Syndromes Are Possible

Capillary malformation-arteriovenous malformation syndrome is another inherited condition associated with fast-flow lesions. It can involve multiple small capillary skin marks together with AVMs or fistulas in soft tissue, bone, brain, or spine. Pathogenic variants in RASA1 or EPHB4 can be involved, and some people have limb overgrowth. The pattern differs from HHT, so the conditions should not be treated as interchangeable. Genetic assessment considers the examination, family history, and appropriate testing. A recognized syndrome can change investigations and counseling for relatives, while a skin mark alone is insufficient to establish the diagnosis. [25]

Sporadic Does Not Mean Genetically Unexplained

Research has identified acquired genetic changes within some AVM tissues. In a 2018 study of sporadic brain AVMs, researchers found activating KRAS variants in many lesion samples, supporting a role for altered cell-signaling pathways. A change confined to affected tissue is different from an inherited variant present throughout the body. The finding therefore does not mean that a person has cancer or that relatives necessarily share the condition. It helps explain AVM biology and suggests research directions. Tissue studies do not, by themselves, establish a reliable blood test, personal rupture forecast, or effective medicine for every brain AVM. [26]

Extracranial Biology Also Varies

A separate study of extracranial AVMs identified somatic MAP2K1 variants, with the changes enriched in cells lining the abnormal vessels and absent from the tested blood or saliva. This supports the idea that a malformation can arise from changes in only part of the body’s cells. It also illustrates why a routine blood-based genetic test may not answer every question about a sporadic lesion. The discovery encouraged investigation of medicines targeting the affected signaling pathway. However, identifying a biological target is an early step; it does not establish that a corresponding drug is safe or effective for routine AVM treatment. [27]

Drug Research Remains Carefully Selected

A small prospective observational study reported improved pain, bleeding, and ulceration in 18 people with severe extracranial AVMs resistant to conventional treatment. Researchers tested thalidomide under specialist supervision. This medicine can cause severe birth defects and requires strict safety precautions. The small sample, lack of randomization, additional procedures, recurrences, and significant adverse effects limit interpretation. These findings do not establish a routine treatment for brain AVMs or a guaranteed cure. Emerging medicines require evaluation of the specific lesion, evidence, and hazards; a promising report does not justify independent use. [28]

Pregnancy Planning Needs Individual Review

Studies of brain-AVM hemorrhage during pregnancy have produced conflicting results, so a universal statement that pregnancy either triggers rupture or adds no risk is too strong. Previous bleeding, lesion anatomy, treatment status, and other maternal conditions all matter to the discussion. When stroke has occurred, Canadian guidance supports coordination between obstetric and stroke specialists, with additional disciplines as needed. Planning should address pregnancy, delivery, anesthesia, and the period after birth. Decisions cannot be reduced to a single percentage from one study. New neurological symptoms during pregnancy still require urgent assessment rather than waiting for a routine appointment. [29]

Children May Need Long-Term Surveillance

An AVM that appears completely eliminated on angiography can occasionally recur, particularly after treatment in childhood or adolescence. A long-term Finnish follow-up study found recurrences among people whose childhood lesions had previously been considered eradicated. The study was small and selected, so its findings should not be turned into a universal recurrence probability. Its practical implication is that successful treatment does not always end follow-up. The specialist team determines which imaging is appropriate and how long surveillance should continue. New symptoms still deserve assessment even after a reassuring earlier scan or a period without problems. [30]

Practical support for AVM care

Prepare a focused appointment agenda

Before a specialist appointment about an AVM, choose the questions you most need answered. Your priorities might be understanding the scan report, comparing the proposed options, or knowing what happens next. Bring a brief medical history and tell the clinician about concerns that could make the plan difficult to follow. Put the most important question first rather than saving it until the visit ends. If several professionals are involved, explain what each has already told you. Ask how to raise questions left unanswered, and request written next steps that you can review after the appointment. [31]

Record context without delaying help

For symptoms already being assessed, a short record can make the next conversation clearer. Note when an episode started, how long it lasted, how often it happened, and what it interrupted in everyday life. Describe what you noticed rather than deciding yourself that every symptom came from the AVM. If someone witnessed an episode, their account may help you explain the sequence. This record is for communication, not home diagnosis. Never postpone urgent assessment to complete a diary: sudden severe headache, stroke symptoms, or other emergency warning signs require immediate emergency help, even if they improve. [32]

Keep records available between teams

An AVM consultation may involve information from several hospitals. Ask the receiving clinic which scan images, reports, procedure summaries, and earlier letters it needs, and how to transfer them securely. A report and the underlying images are different items, so clarify the request. Keep a dated list of where the originals are held and check that the clinic received the requested material. In the United States, HIPAA generally gives patients access to records held by covered providers, subject to exceptions. Elsewhere, ask about the local access process. Query factual errors through the provider’s correction procedure. [33]

Bring an accurate medicine list

Keep an up-to-date list of prescription medicines, nonprescription products, vitamins, and supplements, together with allergies and the reason each medicine was prescribed. Bring it to AVM consultations and share it with the pharmacist or hospital team when requested. Include occasional products rather than listing only daily prescriptions. If a label or instruction is unclear, ask the clinician or pharmacist to reconcile the information. A dated paper copy or accessible phone record can be useful when different services cannot see the same system. The list supports professional review; it does not determine which products are appropriate for you. [34]

Make risk comparisons understandable

When discussing AVM options, ask the specialist to explain benefits and harms with actual numbers, a stated time period, and the same group size for each comparison. Absolute risk describes how many people experience an outcome; a relative change describes the difference in proportion to a starting risk. Hearing only a relative percentage leaves that starting risk unclear. Ask whether the estimate concerns people whose situation resembles yours, what uncertainty remains, and whether a picture would help. Keep different outcomes separate: preventing a future event, experiencing a procedure complication, and improving a symptom answer different questions. [35]

Connect decisions with your priorities

Tell the team which possible outcomes matter most to you, including independence, communication, employment, caregiving, or other personal commitments. Ask how each reasonable AVM option could affect those priorities and what is uncertain. If the recommendation is difficult to understand, request the reasoning and ask whether a further discussion or second opinion would help. Clarify whether there is a deadline for deciding and what delay would mean in your situation. Choose whether you want another person involved. If support becomes pressure, you can ask to speak privately with the clinician before making a decision about your care. [36]

Leave with a usable follow-up plan

Before leaving, check that you understand the issue being addressed, your next step, and why that step matters. For AVM follow-up, turn a vague instruction into a practical plan: who arranges the next appointment, when results should arrive, and which service answers questions between visits. Say the plan back in your own words and ask the team to correct misunderstandings. If a requested result or appointment does not arrive when expected, use the agreed contact route. Keep emergency instructions distinct from routine contact details so a message waiting in an inbox never substitutes for urgent help. [37]

Understand the purpose of each test

When another scan or procedure is proposed, ask what specific question it will answer and how the answer could change your AVM care. Discuss the relevant downsides, alternatives, and implications of waiting with the specialist. These questions help you understand a recommendation; they are not a reason to cancel prescribed surveillance or assume a test is unnecessary. Tell the team about earlier studies so it can decide whether those images are useful. If appointments require substantial travel, ask whether suitable parts of the assessment can happen locally or whether visits can be coordinated without compromising care. [38]

Request communication that works

Tell the clinic in advance if hearing, vision, or speech difficulties make an AVM consultation harder to access. Describe what works for you, such as accessible electronic documents, large print, captioning, a qualified sign-language interpreter, or additional time to communicate. Check that arrangements cover the discussion of risks and choices as well as booking the visit. A relative’s presence does not automatically meet your communication needs. In the United States, ADA guidance explains effective communication duties for covered services; arrangements and legal rights differ elsewhere. Ask the clinic’s accessibility contact to confirm what will be available. [39]

Agree on practical help

Support after an AVM diagnosis can be specific and chosen by the person receiving it. Start with what would actually help: a lift to an appointment, meals during recovery, help organizing letters, or company during a difficult conversation. Agree who will do each task and when, rather than assuming one relative can manage everything. Include the person with the AVM in planning wherever possible and respect the information they want kept private. Review the arrangement when needs change. If family or friends cannot provide enough help, ask the hospital team about community services and caregiver resources. [40]

Plan support for the supporter

Someone helping through AVM appointments or recovery may also need rest, emotional support, and time for their own healthcare. Talk about realistic availability before exhaustion becomes the only signal that help is needed. A break may mean another person handles shopping or accompanies an appointment; it need not involve going away. If replacement care is needed, arrange it in advance and share relevant instructions and contact details with the person’s agreement. Ask local services about assessments, respite, and possible funding. Carers UK provides guidance for UK carers, but eligibility and routes depend on where you live. [41]

Discuss work needs individually

If AVM appointments, symptoms, or recovery affect work, describe the tasks that are difficult and discuss possible adjustments with your employer or occupational health service. Options to explore might include appointment flexibility, different duties, accessible information, or a planned return after absence. Ask your treating team what medical information would help that discussion. Agree how any arrangement will be reviewed as your situation changes. An AVM label alone does not define everyone’s working capacity. Acas explains reasonable adjustments in Great Britain; employment rights, disclosure requirements, and support schemes depend on jurisdiction and individual circumstances, so obtain local advice. [42]

Discuss travel before committing

Before booking a trip, discuss its timing, destination, transport, planned activities, and access to care with the team managing your AVM. Recent treatment or changing symptoms make individualized advice especially important. Ask whether you need a medical summary, assistance during the journey, or coordination with a travel medicine service. Check insurance wording for your circumstances and identify how to obtain medical help at the destination. Keep relevant contact details accessible. CDC guidance encourages people with chronic conditions to plan with their clinicians before paying for nonrefundable travel; it does not provide a universal clearance rule for AVMs. [43]

Raise financial barriers early

If cost could prevent an AVM consultation, scan, or follow-up visit, tell the care team and ask for a financial counselor or social worker. Describe the specific obstacle: insurance approval, travel costs, time away from work, or a bill you do not understand. Keep relevant notices and dates together so an adviser can see what needs attention. In the United States, Patient Advocate Foundation offers case management for eligible people facing serious health conditions, including insurance and financial barriers. Its programs have eligibility rules and availability limits; an AVM diagnosis does not automatically guarantee assistance or funding. [44]

Use peer support thoughtfully

Talking with others who have faced a brain AVM can offer companionship and ideas for navigating appointments, recovery, or family conversations. The Aneurysm and AVM Foundation provides groups for people affected by brain AVMs and related conditions, including caregivers. Check the current format and participation details before joining. Share only what you are comfortable discussing, and bring medical claims back to your own team. Another person’s treatment choice or recovery story cannot predict your outcome. If worry is disrupting daily life, tell a healthcare professional; a support group can accompany professional help without replacing an individual assessment. [45]

Frequently asked questions

Does every brain AVM need surgery?

No. Observation and intervention both require individualized assessment of bleeding risk, anatomy, symptoms, and treatment risks. [20]

Does radiosurgery work immediately?

No. Vessel closure develops gradually, may remain incomplete, and requires follow-up imaging; bleeding risk persists during the waiting period. [18]

Is embolization always a cure?

No. It may prepare for another treatment or address selected vessels; partial embolization does not establish complete AVM elimination. [19]

Are AVMs always inherited?

No. Some occur with inherited syndromes such as HHT; clinical features and family history determine whether genetic assessment is appropriate. [24]

Can a brain AVM recur after treatment?

Recurrence is possible, particularly after childhood treatment, so specialists may recommend continuing surveillance despite earlier evidence of complete elimination. [30]

Does a low surgical grade predict bleeding?

The Spetzler-Martin grade estimates operative risk; it does not independently calculate an AVM’s spontaneous rupture risk. [16]